An Introduction to Esophageal Cancer Treatment
Esophageal cancer, a cancer that forms in the tube connecting the throat to the stomach, requires a complex and highly individualized treatment plan. The therapeutic strategy is determined by a careful evaluation of several critical factors. The most important of these are the cancer’s specific type (most commonly adenocarcinoma or squamous cell carcinoma) and its stage, which defines the tumor’s size, depth of invasion, and whether it has spread to lymph nodes or distant organs. The tumor’s location within the esophagus and the patient’s overall health and ability to tolerate aggressive treatment are also key considerations.
Treatment goals are defined by the cancer’s stage. For very early-stage cancers, the goal is curative with minimally invasive procedures. For locally advanced disease, the intent is also curative, but this requires an intensive, multi-modal approach combining chemotherapy, radiation, and surgery. For metastatic cancer that has spread to distant sites, the disease is not curable, and the goals of treatment shift to slowing the cancer’s growth, managing symptoms like difficulty swallowing, and maintaining quality of life.
The Role of the Multidisciplinary Team (MDT)
The management of esophageal cancer is a complex undertaking that requires the integrated expertise of a multidisciplinary team. This collaborative group of specialists is essential for accurate diagnosis and staging, developing the optimal treatment sequence, and managing the significant side effects of therapy.
The core members of an esophageal cancer MDT include:
- Gastroenterologist: A specialist who diagnoses the cancer through an upper endoscopy and may perform endoscopic treatments for very early-stage disease.
- Thoracic Surgeon or Surgical Oncologist: A surgeon with specific expertise in operating on the esophagus.
- Medical Oncologist: A physician who manages systemic therapies, including chemotherapy, targeted therapy, and immunotherapy.
- Radiation Oncologist: A doctor who specializes in planning and delivering radiation therapy.
- Pathologist: A physician who examines the tumor tissue from a biopsy to confirm the diagnosis and identify its type and molecular features.
- Radiologist: A physician who interprets imaging scans like CT and PET to accurately stage the cancer.
- Registered Dietitian: A nutrition expert who plays a vital role in managing the significant nutritional challenges associated with the disease and its treatment.
Treatment for Very Early-Stage Esophageal Cancer
For small, superficial cancers that are confined to the innermost layer of the esophageal lining (the mucosa), it is sometimes possible to treat the disease without major surgery. These minimally invasive procedures are performed by a skilled gastroenterologist during an upper endoscopy.
- Endoscopic Mucosal Resection (EMR): A solution is injected underneath the small tumor to lift it away from the deeper layers. A wire snare passed through the endoscope is then used to cut the tumor off.
- Endoscopic Submucosal Dissection (ESD): This is a more advanced technique that allows for the removal of slightly larger or flatter superficial tumors in a single piece.
- Ablation Therapies: Techniques like radiofrequency ablation (RFA) can be used after EMR to destroy any remaining abnormal tissue in the area to prevent recurrence.
These endoscopic options are only suitable for a select group of patients whose cancer is determined to be very early stage after a thorough evaluation.
Treatment for Locally Advanced (Resectable) Esophageal Cancer
For most patients who are diagnosed with esophageal cancer, the tumor has grown deeper into the wall of the esophagus or has spread to nearby lymph nodes, but not yet to distant organs. For this “locally advanced” stage, the standard-of-care, curative-intent treatment is a multi-modal approach that typically involves chemotherapy, radiation, and surgery.
- Neoadjuvant Therapy: The most common strategy is to begin treatment before surgery with several weeks of concurrent chemotherapy and radiation therapy (chemoradiation). This “neoadjuvant” approach has two key benefits: it shrinks the primary tumor and treats the affected lymph nodes, which increases the chance that the surgeon can remove all of the cancer successfully. It also treats any microscopic cancer cells that may have already spread.
- Surgery (Esophagectomy): After the neoadjuvant therapy is complete and the patient has had time to recover, surgery is performed. An esophagectomy is a major and complex operation that involves removing the portion of the esophagus containing the tumor. The stomach is then pulled up into the chest and reconnected to the remaining part of the esophagus to restore the digestive tract. During the surgery, the surgeon also removes the lymph nodes around the esophagus and stomach for staging.
In some cases, chemotherapy alone may be given before surgery, or surgery may be performed first, followed by adjuvant (post-operative) chemotherapy or chemoradiation. The specific sequence of treatments is determined by the MDT.
Treatment for Unresectable or Metastatic Esophageal Cancer
If the cancer has grown to invade critical nearby structures (like the aorta or the airway), making it unresectable, or if it has spread to distant organs (metastatic disease), it is not considered curable. Treatment focuses on palliative care to control the disease and its symptoms.
- Systemic Therapy: The primary treatment is systemic therapy with drugs that travel through the bloodstream.
- Chemotherapy: Platinum-based chemotherapy is the foundation of treatment to shrink tumors and alleviate symptoms.
- Immunotherapy: Immune checkpoint inhibitors, which help the body’s own immune system attack cancer, have become a first-line standard of care for many patients with advanced esophageal cancer. They are often given in combination with chemotherapy.
- Targeted Therapy: For the subset of esophageal adenocarcinomas that are “HER2-positive,” a targeted drug that blocks the HER2 protein can be added to chemotherapy.
- Radiation Therapy: Radiation can be very effective as a palliative tool. It can be used to shrink a tumor that is causing pain or to help relieve difficulty swallowing (dysphagia).
- Symptom Management (Dysphagia): Difficulty swallowing is a major symptom of advanced esophageal cancer. To relieve a blockage, a gastroenterologist can place an expandable metal tube (an esophageal stent) inside the esophagus to hold it open and allow the patient to eat and drink more comfortably.
Nutritional Support: A Critical Component of Care
Adequate nutrition is a major challenge for patients with esophageal cancer. Difficulty swallowing can lead to significant weight loss and malnutrition even before treatment begins. The treatments themselves, particularly chemoradiation and surgery, further impact the ability to eat.
A registered dietitian is a key member of the care team. To ensure patients receive enough nutrition to tolerate and recover from treatment, a feeding tube is often placed before therapy begins. A common type is a jejunostomy tube (J-tube), which is a small tube surgically placed through the skin directly into the small intestine, bypassing the esophagus and stomach. This allows for liquid nutrition to be delivered directly into the digestive system.
Frequently Asked Questions
1. What is the difference between adenocarcinoma and squamous cell carcinoma of the esophagus?
Adenocarcinoma is the most common type in many Western countries and typically arises in the lower part of the esophagus, often in connection with chronic acid reflux and a condition called Barrett’s esophagus. Squamous cell carcinoma arises from the flat cells lining the esophagus and is more common in the upper and middle portions. It is more strongly associated with smoking and heavy alcohol consumption. While some treatments overlap, the choice of systemic therapy can differ based on the type.
2. What does “neoadjuvant therapy” mean?
Neoadjuvant therapy is any treatment—such as chemotherapy, radiation therapy, or both—that is given before the main treatment, which is usually surgery. For locally advanced esophageal cancer, neoadjuvant chemoradiation is used to shrink the tumor and treat affected lymph nodes, making a subsequent surgery more likely to be successful.
3. What is an esophagectomy?
An esophagectomy is a major surgical operation to remove all or part of the esophagus. It is the primary surgical procedure for esophageal cancer. After the cancerous portion of the esophagus is removed, the surgeon reconstructs the digestive tract, most commonly by pulling the stomach up into the chest and connecting it to the remaining esophagus.
4. Why is a feeding tube often needed during treatment?
The tumor itself can make it difficult to swallow, and the side effects of chemoradiation (such as esophagitis) and the recovery from an esophagectomy further compromise a patient’s ability to eat normally. A feeding tube is placed to provide essential liquid nutrition directly into the stomach or intestine, ensuring the patient can maintain their weight and strength to better tolerate the intensive cancer treatments.
5. Is surgery always the main treatment for esophageal cancer?
No. While surgery is the cornerstone of curative therapy for resectable cancer, it is not used in all situations. For very early-stage superficial cancers, endoscopic removal may be sufficient. For locally advanced disease, surgery is part of a multi-modal plan that includes chemoradiation. For metastatic disease, surgery is not used, and treatment relies on systemic medications like chemotherapy and immunotherapy.
6. What is the purpose of an esophageal stent?
An esophageal stent is a flexible, expandable mesh tube that is placed inside the esophagus to open up a blockage caused by a tumor. It is a palliative procedure used for patients with advanced cancer to relieve the symptom of dysphagia (difficulty swallowing), allowing them to eat and drink more comfortably and improving their quality of life.
7. How has immunotherapy changed the treatment for advanced esophageal cancer?
Immunotherapy with drugs called checkpoint inhibitors has become a first-line treatment for many patients with advanced or metastatic esophageal cancer. By “unleashing” the body’s own immune system to fight the cancer, these drugs, often combined with chemotherapy, have shown the ability to improve outcomes and have become a new standard of care.
